In this presentation Dr Khan talks about many case studies involving Transitional cell carcinoma (TCC), colon cancer and Adenoid cystic carcinoma (ACC), explaining how Low Dose Naltrexone (LDN) can improve the lives of cancer patients.
Low Dose Naltrexone (LDN) is also discussed in terms of its ability to prevent the spread of cancer. The science behind LDN’s mechanism of action within the body is also discussed, touching upon opioid growth factors and T-lymphocytes.
This is a summary of Dr Akbar Khan’s presentation. Please listen to the rest of Dr Khan’s story by clicking on the video above.
To watch past conference click https://ldnresearchtrust.org/ldn-conferences